Hims & Hers Health (HIMS) Stock Slides 15% Despite Strong Revenue Growth
Hims & Hers Health (HIMS) shares have tumbled more than 15% since last week, with bears pointing to GLP-1 dependence, margin pressures, and increased spending as threats to the telehealth company's future. Yet beneath the surface, the business continues to grow—Q3 revenue surged 49% year-over-year to nearly $600 million, supported by almost 2.5 million subscribers and sustained profitability.
The company is evolving beyond a weight-loss focus into a broader consumer health platform, a strategic shift that could justify its current valuation. While skeptics fixate on short-term headwinds, the long-term case for HIMS hinges on its ability to expand its ecosystem and capitalize on compounding demand.